Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis

Molecular Cell

Volumn 13, Issue 5, 2004, Pages 627-638

  Cohen, Haim Y ^a   Lavu, Siva ^a   Bitterman, Kevin J ^a   Hekking, Brian ^a   Imahiyerobo, Thomas A ^a   Miller, Christine ^a   Frye, Roy ^b   Ploegh, Hidde ^a   Kessler, Benedikt M ^a   Sinclair, David A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; DNA; ENZYME INHIBITOR; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE CBP; HISTONE ACETYLTRANSFERASE PCAF; KU ANTIGEN; LYSINE; PROTEIN BAX; UNCLASSIFIED DRUG;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; ENZYME ACTIVITY; GENE DISRUPTION; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SECRETION;

ACETYLATION; ACETYLTRANSFERASES; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NUCLEAR; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BINDING SITES; CREB-BINDING PROTEIN; CRICETINAE; DNA HELICASES; DNA-BINDING PROTEINS; ENZYME INHIBITORS; HELA CELLS; HISTONE ACETYLTRANSFERASES; HUMANS; LYSINE; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SEQUENCE HOMOLOGY, AMINO ACID; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 12144286529     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(04)00094-2     Document Type: Article

References (56)

1. Abraham J., Kelly J., Thibault P., Benchimol S. Post-translational modification of p53 protein in response to ionizing radiation analyzed by mass spectrometry. J. Mol. Biol. 295:2000;853-864.
2. Bertinato J., Schild-Poulter C., Hache R.J. Nuclear localization of Ku antigen is promoted independently by basic motifs in the Ku70 and Ku80 subunits. J. Cell Sci. 114:2001;89-99.
3. Bitterman K.J., Anderson R.M., Cohen H.Y., Latorre-Esteves M., Sinclair D.A. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast Sir2 and human SIRT1. J. Biol. Chem. 277:2002;45099-45107.
4. Blobel G.A. CREB-binding protein and p300. molecular integrators of hematopoietic transcription Blood. 95:2000;745-755.
5. Brown C.E., Lechner T., Howe L., Workman J.L. The many HATs of transcription coactivators. Trends Biochem. Sci. 25:2000;15-19.
6. Chan H.M., La Thangue N.B. p300/CBP proteins. HATs for transcriptional bridges and scaffolds J. Cell Sci. 114:2001;2363-2373.
7. Chan D.W., Ye R., Veillette C.J., Lees-Miller S.P. DNA-dependent protein kinase phosphorylation sites in Ku 70/80 heterodimer. Biochemistry. 38:1999;1819-1828.
8. Chan H.M., Krstic-Demonacos M., Smith L., Demonacos C., La Thangue N.B. Acetylation control of the retinoblastoma tumour-suppressor protein. Nat. Cell Biol. 3:2001;667-674.
9. Chechlacz M., Vemuri M.C., Naegele J.R. Role of DNA-dependent protein kinase in neuronal survival. J. Neurochem. 78:2001;141-154.
10. Coffey G., Lakshmipathy U., Campbell C. Mammalian mitochondrial extracts possess DNA end-binding activity. Nucleic Acids Res. 27:1999;3348-3354.
11. Costanzo A., Merlo P., Pediconi N., Fulco M., Sartorelli V., Cole P.A., Fontemaggi G., Fanciulli M., Schiltz L., Blandino G.et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell. 9:2002;175-186.
12. Evan G.I., Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature. 411:2001;342-348.
13. Featherstone C., Jackson S.P. Ku, a DNA repair protein with multiple cellular functions? Mutat. Res. 434:1999;3-15.
14. Giles R.H., Dauwerse J.G., Higgins C., Petrij F., Wessels J.W., Beverstock G.C., Dohner H., Jotterand-Bellomo M., Falkenburg J.H., Slater R.M. et al. Detection of CBP rearrangements in acute myelogenous leukemia with t(8;16). Leukemia. 11:1997;2087-2096.
15. Giordano A., Avantaggiati M.L. p300 and CBP. partners for life and death J. Cell. Physiol. 181:1999;218-230.
16. Grossman S.R. p300/CBP/p53 interaction and regulation of the p53 response. Eur. J. Biochem. 268:2001;2773-2778.
17. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 90:1997;595-606.
18. Gu Y., Sekiguchi J., Gao Y., Dikkes P., Frank K., Ferguson D., Hasty P., Chun J., Alt F.W. Defective embryonic neurogenesis in Ku-deficient but not DNA-dependent protein kinase catalytic subunit-deficient mice. Proc. Natl. Acad. Sci. USA. 97:2000;2668-2673.
19. Ida K., Kitabayashi I., Taki T., Taniwaki M., Noro K., Yamamoto M., Ohki M., Hayashi Y. Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13). Blood. 90:1997;4699-4704.
20. Johnstone R.W., Licht J.D. Histone deacetylase inhibitors in cancer therapy. Is transcription the primary target? Cancer Cell. 4:2003;13-18.
21. Kim S.H., Kim D., Han J.S., Jeong C.S., Chung B.S., Kang C.D., Li G.C. Ku autoantigen affects the susceptibility to anticancer drugs. Cancer Res. 59:1999;4012-4017.
22. Kinter M., Sherman N.E. Protein Sequencing Identification Using Tandem Mass Spectrometry. 2000;Wiley and Sons, New York.
23. Kouzarides T. Acetylation. a regulatory modification to rival phosphorylation? EMBO J. 19:2000;1176-1179.
24. Kung A.L., Rebel V.I., Bronson R.T., Ch'ng L.E., Sieff C.A., Livingston D.M., Yao T.P. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev. 14:2000;272-277.
25. Lai J.S., Herr W. Ethidium bromide provides a simple tool for identifying genuine DNA-independent protein associations. Proc. Natl. Acad. Sci. USA. 89:1992;6958-6962.
26. Landry J., Slama J.T., Sternglanz R. Role of NAD(+) in the deacetylase activity of the SIR2-like proteins. Biochem. Biophys. Res. Commun. 278:2000;685-690.
27. Li M., Luo J., Brooks C.L., Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 277:2002;50607-50611.
28. Liu L., Scolnick D.M., Trievel R.C., Zhang H.B., Marmorstein R., Halazonetis T.D., Berger S.L. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell. Biol. 19:1999;1202-1209.
29. Liu Y., Colosimo A.L., Yang X.J., Liao D. Adenovirus E1B 55-kilodalton oncoprotein inhibits p53 acetylation by PCAF. Mol. Cell. Biol. 20:2000;5540-5553.
30. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 107:2001;137-148.
31. Manis J.P., Gu Y., Lansford R., Sonoda E., Ferrini R., Davidson L., Rajewsky K., Alt F.W. Ku70 is required for late B cell development and immunoglobulin heavy chain class switching. J. Exp. Med. 187:1998;2081-2089.
32. Muraoka M., Konishi M., Kikuchi-Yanoshita R., Tanaka K., Shitara N., Chong J.M., Iwama T., Miyaki M. p300 gene alterations in colorectal and gastric carcinomas. Oncogene. 12:1996;1565-1569.
33. Nothwehr S.F., Martinou J.C. A retention factor keeps death at bay. Nat. Cell Biol. 5:2003;281-283.
34. Ogryzko V.V., Schiltz R.L., Russanova V., Howard B.H., Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 87:1996;953-959.
35. Ouyang H., Nussenzweig A., Kurimasa A., Soares V.C., Li X., Cordon-Cardo C., Li W., Cheong N., Nussenzweig M., Iliakis G.et al. Ku70 is required for DNA repair but not for T cell antigen receptor gene recombination in vivo. J. Exp. Med. 186:1997;921-929.
36. Ozdag H., Batley S.J., Forsti A., Iyer N.G., Daigo Y., Boutell J., Arends M.J., Ponder B.A., Kouzarides T., Caldas C. Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours. Br. J. Cancer. 87:2002;1162-1165.
37. Perkins D.N., Pappin D.J., Creasy D.M., Cottrell J.S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 20:1999;3551-3567.
38. Phillips A.C., Vousden K.H. Acetyltransferases and tumour suppression. Breast Cancer Res. 2:2000;244-246.
39. Rahman M.M., Kukita A., Kukita T., Shobuike T., Nakamura T., Kohashi O. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood. 101:2003;3451-3459.
40. Rampino N., Yamamoto H., Ionov Y., Li Y., Sawai H., Reed J.C., Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 275:1997;967-969.
41. Rebel V.I., Kung A.L., Tanner E.A., Yang H., Bronson R.T., Livingston D.M. Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc. Natl. Acad. Sci. USA. 99:2002;14789-14794.
42. Sakaguchi K., Herrera J.E., Saito S., Miki T., Bustin M., Vassilev A., Anderson C.W., Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:1998;2831-2841.
43. Sawada M., Hayes P., Matsuyama S. Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70. Nat. Cell Biol. 5:2003;352-357. a.
44. Sawada M., Sun W., Hayes P., Leskov K., Boothman D.A., Matsuyama S. Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat. Cell Biol. 5:2003;320-329. b.
45. Schiltz R.L., Nakatani Y. The PCAF acetylase complex as a potential tumor suppressor. Biochim. Biophys. Acta. 1470:2000;M37-M53.
46. Scorrano L., Korsmeyer S.J. Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem. Biophys. Res. Commun. 304:2003;437-444.
47. Sugita K., Taki T., Hayashi Y., Shimaoka H., Kumazaki H., Inoue H., Konno Y., Taniwaki M., Kurosawa H., Eguchi M. MLL-CBP fusion transcript in a therapy-related acute myeloid leukemia with the t(11;16)(q23;p13) which developed in an acute lymphoblastic leukemia patient with Fanconi anemia. Genes Chromosomes Cancer. 27:2000;264-269.
48. Tillinghast G.W., Partee J., Albert P., Kelley J.M., Burtow K.H., Kelly K. Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines. Genes Chromosomes Cancer. 37:2003;121-131.
49. Tuteja R., Tuteja N. Ku autoantigen. a multifunctional DNA-binding protein Crit. Rev. Biochem. Mol. Biol. 35:2000;1-33.
50. Walker J.R., Corpina R.A., Goldberg J. Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair. Nature. 412:2001;607-614.
51. Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C. Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305. J. Biol. Chem. 278:2003;25568-25576.
52. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B., Korsmeyer S.J. Proapoptotic BAX and BAK. a requisite gateway to mitochondrial dysfunction and death Science. 292:2001;727-730.
53. Yoshida M., Horinouchi S. Trichostatin and leptomycin. Inhibition of histone deacetylation and signal-dependent nuclear export. Ann. N Y Acad. Sci. 886:1999;23-36.
54. Yoshida M., Furumai R., Nishiyama M., Komatsu Y., Nishino N., Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 48:2001;S20-S26.
55. Yuan L.W., Soh J.W., Weinstein I.B. Inhibition of histone acetyltransferase function of p300 by PKCdelta. Biochim. Biophys. Acta. 1592:2002;205-211.
56. Zhang Z., Zhu L., Lin D., Chen F., Chen D.J., Chen Y. The three-dimensional structure of the C-terminal DNA-binding domain of human Ku70. J. Biol. Chem. 276:2001;38231-38236.